BACKGROUND: Some elderly patients may have reduced tolerance the standard therapy (chemotherapy doublets) for stage III/IV non-small cell lung cancer (NSCLC). Sunitinib malate (S), an oral, multitargeted kinase inhibitor, shows promise as 2nd-line NSCLC treatment. This study explored the safety/efficacy of S in elderly patients with previously untreated NSCLC. PRIMARY OBJECTIVE: disease control rate (DCR) at six-weeks. SECONDARY OBJECTIVES: overall response (OR, CR+PR), progression-free survival (PFS), time to progression (TTP), one-yr survival, quality of life (QOL), and safety. TREATMENT: S 37.5 mg daily/42-day cycle until PD or intolerable toxicity. Key inclusion: chemo-naïve stage IIIB/IV NSCLC (nonsquamous histology); ECOG PS=0-1; ≥ 70 years; normal organ function. Exclusion: hemoptysis, anticoagulation, or clotting diathesis. Other standard S-specific criteria applied. RESULTS: 63 patients enrolled/60 treated. DEMOGRAPHICS: 51 % male, 95 % white, median age 78 years (range, 70-88), 73 % ECOG=1, 97 % Stage IV, 83 % adenocarcinoma, 44 % prior surgery, 19 % prior radiation. With a median of 2 cycles (range, 1-16), DCR=63 %, OR=7 % (0 CR, 4 PR). Median follow-up=5.8 months (all; 15.9 months survivors), median PFS =3.0 months (range, <1-25.1), median TTP=4.5 months (range, <1-25.1), and 1-year survival=26.4 % [95 % CI: 15.9, 38.2]. QOL declined initially, but improved over time. TREATMENT-related adverse events included: fatigue (48.3 %); diarrhea (38.3 %); thrombocytopenia (33.3 %), anorexia (26.7 %), mucositis (25.0 %); nausea (25.0 %), dysgeusia (20.0 %), and neutropenia (20.0 %). Conclusions The study met its primary endpoint. S produced acceptable DCR and QOL improved; however, OR was disappointing (7 %) and toxicity was greater than expected. A biomarker to identify patients more likely to benefit from S is needed.
BACKGROUND: Some elderly patients may have reduced tolerance the standard therapy (chemotherapy doublets) for stage III/IV non-small cell lung cancer (NSCLC). Sunitinib malate (S), an oral, multitargeted kinase inhibitor, shows promise as 2nd-line NSCLC treatment. This study explored the safety/efficacy of S in elderly patients with previously untreated NSCLC. PRIMARY OBJECTIVE: disease control rate (DCR) at six-weeks. SECONDARY OBJECTIVES: overall response (OR, CR+PR), progression-free survival (PFS), time to progression (TTP), one-yr survival, quality of life (QOL), and safety. TREATMENT: S 37.5 mg daily/42-day cycle until PD or intolerable toxicity. Key inclusion: chemo-naïve stage IIIB/IV NSCLC (nonsquamous histology); ECOG PS=0-1; ≥ 70 years; normal organ function. Exclusion: hemoptysis, anticoagulation, or clotting diathesis. Other standard S-specific criteria applied. RESULTS: 63 patients enrolled/60 treated. DEMOGRAPHICS: 51 % male, 95 % white, median age 78 years (range, 70-88), 73 % ECOG=1, 97 % Stage IV, 83 % adenocarcinoma, 44 % prior surgery, 19 % prior radiation. With a median of 2 cycles (range, 1-16), DCR=63 %, OR=7 % (0 CR, 4 PR). Median follow-up=5.8 months (all; 15.9 months survivors), median PFS =3.0 months (range, <1-25.1), median TTP=4.5 months (range, <1-25.1), and 1-year survival=26.4 % [95 % CI: 15.9, 38.2]. QOL declined initially, but improved over time. TREATMENT-related adverse events included: fatigue (48.3 %); diarrhea (38.3 %); thrombocytopenia (33.3 %), anorexia (26.7 %), mucositis (25.0 %); nausea (25.0 %), dysgeusia (20.0 %), and neutropenia (20.0 %). Conclusions The study met its primary endpoint. S produced acceptable DCR and QOL improved; however, OR was disappointing (7 %) and toxicity was greater than expected. A biomarker to identify patients more likely to benefit from S is needed.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Regina Gironés; Dolores Torregrosa; José Gómez-Codina; Inma Maestu; Jose Maria Tenias; Rafael Rosell Journal: Lung Cancer Date: 2010-08-19 Impact factor: 5.705
Authors: O S Breathnach; B Freidlin; B Conley; M R Green; D H Johnson; D R Gandara; M O'Connell; F A Shepherd; B E Johnson Journal: J Clin Oncol Date: 2001-03-15 Impact factor: 44.544
Authors: B Biesma; A N M Wymenga; A Vincent; O Dalesio; H J M Smit; J A Stigt; E F Smit; C L van Felius; J W G van Putten; J P J Slaets; H J M Groen Journal: Ann Oncol Date: 2011-01-20 Impact factor: 32.976
Authors: Marcus A Neubauer; Craig H Reynolds; Marcos G Joppert; Thomas Whitaker; Habib Ghaddar; Thomas A Marsland; Lina Asmar Journal: Clin Lung Cancer Date: 2005-01 Impact factor: 4.785
Authors: Suresh S Ramalingam; Suzanne E Dahlberg; Corey J Langer; Robert Gray; Chandra P Belani; Julie R Brahmer; Alan B Sandler; Joan H Schiller; David H Johnson Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara Journal: J Clin Oncol Date: 2008-05-27 Impact factor: 44.544
Authors: Benjamin Carlisle; Nadine Demko; Georgina Freeman; Amanda Hakala; Nathalie MacKinnon; Tim Ramsay; Spencer Hey; Alex John London; Jonathan Kimmelman Journal: J Natl Cancer Inst Date: 2015-11-07 Impact factor: 13.506
Authors: Manuela Gridling; Scott B Ficarro; Florian P Breitwieser; Lanxi Song; Katja Parapatics; Jacques Colinge; Eric B Haura; Jarrod A Marto; Giulio Superti-Furga; Keiryn L Bennett; Uwe Rix Journal: Mol Cancer Ther Date: 2014-09-04 Impact factor: 6.261